Results 261 to 270 of about 231,111 (314)

Active specific immunotherapy of melanoma

British Medical Bulletin, 1995
Active specific immunotherapy, or the use of tumor 'vaccines', attempts to stimulate the patient to reject his or her tumor. Nowhere has this approach been utilized more than in melanoma, often with encouraging results. The best results have occurred in the setting of minimal residual disease after resection of the primary tumor and involved lymph ...
openaire   +2 more sources

Active specific immunotherapy for colorectal cancer

Expert Review of Anticancer Therapy, 2003
With advances in molecular biology and the identification of tumor-associated antigens, a number of new strategies have been developed in an attempt to overcome the limits of chemotherapy and to aid in the fight to cure patients of metastatic and micrometastatic colorectal carcinomas.
Adrian A, Indar, Charles A, Maxwell-Armstrong   +1 more
openaire   +2 more sources

Active specific immunotherapy in malignant melanoma

Seminars in Surgical Oncology, 1989
AbstractWe have recently initiated clinical trials of active specific immunotherapy evaluating a new polyvalent melanoma cell vaccine in patients with high‐risk and/or recurrent melanoma. The vaccine has been administered alone, or in combination with low‐dose cyclophosphamide, as an immunomodulator of suppressor cells. Cyclophosphamide is effective in
D L, Morton, L J, Foshag, J A, Nizze, R K, Gupta, E, Famatiga, D S, Hoon, R F, Irie   +6 more
openaire   +2 more sources

Immunotherapy Activates Antitumor γ9δ2 T Cells

Cancer Discovery, 2021
Abstract Following preclinical data demonstrating that treatment with the monoclonal BNT3A antibody ICT01 can activate unique antitumor γ9δ2 T cells and encourage their trafficking to tumors, a phase I/IIa, first-in-human clinical trial of the agent is under way. Early data show corresponding results in ICT01-treated patients.
openaire   +2 more sources

ACTIVE SPECIFIC IMMUNOTHERAPY FOR OVARIAN CANCER

The Lancet, 1976
Ten patients with advanced or recurrent ovarian cancer were treated with a combination of chemotherapy and active specific immunotherapy after tumour stasis had been induced. They were inoculated with irradiated allogeneic cryopreserved tumour cells and B.C.G. once monthly in addition to receiving conventional chemotherapy.
C N, Hudson, J E, McHardy, O M, Curling, P E, English, L, Levin, T A, Poulton, M, Crowther, M, Leighton   +7 more
openaire   +2 more sources

ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA

The Lancet, 1969
Abstract Active immunotherapy (with B.C.G. and/or vaccination from a pool of allogeneic leukaemic " lymphoblasts " pretreated with formalin or irradiated in vitro) has been given to patients with acute lymphoblastic leukaemia who had previously been treated by chemotherapy, to induce a remission, and by complementary chemotherapy designed to reduce ...
G, Mathé, J L, Amiel, L, Schwarzenberg, M, Schneider, A, Cattan, J R, Schlumberger, M, Hayat, F, De Vassal   +7 more
openaire   +2 more sources

Active immunotherapy in follicular lymphoma

Seminars in Cancer Biology, 2003
The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens ("idiotypes"). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses ...
openaire   +3 more sources

Adoptive Immunotherapy, Active Specific Immunotherapy, Biological Response Modifiers

1989
G. Parmiani (Milano) outlined developments in the use of adoptive immunotherapy in cancer in the last 5 years. It has been established that a type of lymphocyte known as the LAK cell (lymphocyte-activated killer) can be used as an effector to overcome the problem of the weak or non-existent immunogenicity of most malignant rodent and human tumours, and
E. Hersh, T. Giraldi
openaire   +1 more source

Systemic Active Immunotherapy

1976
When we started the first clinical controlled trial or active immunotherapy in 1963 (MATHS et al., 1968, 1969a), the favourable tumour growth plate of the immune balance was not known. Nevertheless, it appeared reasonable to conduct experiments on active immunotherapy of experimental established tumours, and to apply them to man in the conditions and ...
openaire   +1 more source

Active Specific Immunotherapy in Ovarian Cancer

1979
The rationale of any programme of active specific immunotherapy depends on the demonstration of appropriate tumour-directed, cell-mediated immune responses, and agents designed to manipulate these immunological responses must be shown to have some therapeutic effect.
M E, Crowther, L, Levin, T A, Poulton, M J, Saffrey, O M, Curling, C N, Hudson   +5 more
openaire   +2 more sources